CRTC1 and renal cell adenocarcinoma: Five additional patients with RCC achieved PRs: three TORC1 inhibitor–naïve (5 mg QD, 30 mg QW, and 40 mg QW) for an ORR of 22%, and two with TORC1 inhibitor failure (both 5 mg QD) for an ORR of 9%.